ALB and coronary artery disorder: Here we evaluated the trisaccharide Galα1,3Galβ1,4GlcNAc (Galα3LN), also known as the Galili or α-Gal epitope or glycotope,26 coupled to the carrier protein human serum albumin (Galα3LN-HSA), in the presence or not of adjuvant liposomal-monophosphoryl lipid A (LMPLA), as a potential experimental vaccine to acute ChD.